Abstract
Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020. Methods: We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion. Results: Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity. Discussion: ADNI has had a profound impact in improving clinical trials for AD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 824-857 |
| Number of pages | 34 |
| Journal | Alzheimer's and Dementia |
| Volume | 18 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2022 |
Keywords
- AV1541 tau positron emission tomography
- Alzheimer's disease
- amyloid
- disease progression
- mild cognitive impairment
- plasma biomarker
- tau
ASJC Scopus subject areas
- Epidemiology
- Health Policy
- Developmental Neuroscience
- Clinical Neurology
- Geriatrics and Gerontology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health